CEO Faheem Hasnain was paid $2,300,455 in fiscal year 2025, ↑ up 14.7% from fiscal year 2024, the 24th percentile of its disclosed peer group (SEC filing 0001728117-26-000027 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,300,455 ↑ Faheem Hasnain total, FY2025 | 24th CEO pay percentile vs peers | — CEO-to-median pay ratio | 93.65% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
GOSS's next annual pay disclosure, estimated April 19, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Faheem Hasnain | $649,649 | $0 | $0 | $1,392,006 | $254,800 | $0 | $4,000 | $2,300,455 |
| Chairman, President and Chief Executive Officer | ||||||||
| Bryan Giraudo | 519,830 | 0 | 0 | 576,688 | 152,913 | 0 | 4,000 | 1,253,431 |
| Chief Operating Officer and Chief Financial Officer | ||||||||
| Robert Smith | 463,500 | 75,000 | 0 | 517,031 | 121,213 | 0 | 4,000 | 1,180,744 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Faheem Hasnain | $2,300,455 | $2,005,432 | $2,095,988 | ↑ +295,023 |
| Bryan Giraudo | 1,253,431 | 1,171,904 | 1,287,882 | ↑ +81,527 |
| Robert Smith | 1,180,744 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Gossamer Bio's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper GOSS reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name GOSS as a peer is temporarily unavailable — recheck shortly.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Faheem Hasnain | CEO | $2,300,455 |
| Bryan Giraudo | CFO | $1,253,431 |
| Robert Smith | CCO | $1,180,744 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| John Quisel, Ph.D., J.D | Independent Director | $172,069 |
| Russell Cox | Independent Director | $186,319 |
| Sandra Milligan, M.D., J.D | Independent Director | $179,319 |
| Skye Drynan | Independent Director | $181,444 |
| Steven Nathan, M.D | Independent Director | $167,444 |
| Thomas Daniel, M.D | Lead Independent Director | $199,569 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Steven D. Nathan | Director | 2026-06-04 | A | 115,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Milligan | Director | 2026-06-04 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Russell Cox | Director | 2026-06-04 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas O. Daniel | Director | 2026-06-04 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Skye Drynan | Director | 2026-06-04 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John D. Quisel | Director | 2026-06-04 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Faheem Hasnain | Director | 2026-08-24 | A | 5,800,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bryan Giraudo | COO/CFO | 2026-08-24 | A | 5,800,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Caryn Peterson | Chief Development Officer | 2026-08-24 | A | 5,800,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Waage Christian | EVP, Tech Ops and Admin | 2026-08-24 | A | 2,900,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bryan Giraudo | COO/CFO | 2026-08-24 | A | 25 | 1,000 | 25,000 | Derivative, Class A Common | Form 4 ↗ |
| Robert Smith | Chief Commercial Officer | 2026-08-24 | A | 5,800,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Faheem Hasnain | Director | 2026-08-24 | A | 166 | 1,000 | 166,000 | Derivative, Class A Common | Form 4 ↗ |
| Steven D. Nathan | Director | 2026-09-23 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Russell Cox | Director | 2026-09-23 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John D. Quisel | Director | 2026-09-23 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Skye Drynan | Director | 2026-09-23 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory Austin Ciongoli | Director | 2026-09-23 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas O. Daniel | Director | 2026-09-23 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Milligan | Director | 2026-09-23 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Faheem Hasnain | OPTION | — | — | — | — | — | $1,392,006 |
| Bryan Giraudo | OPTION | — | — | — | — | — | 576,688 |
| Robert Smith | OPTION | — | — | — | — | — | 517,031 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Faheem Hasnain | $0 | $0 | $1,392,006 | 0.0% |
| Bryan Giraudo | 0 | 0 | 576,688 | 0.0% |
| Robert Smith | 0 | 0 | 517,031 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bryan Giraudo | Option | 638,000 | 1.13 | — |
| Robert Smith | PSU | 162,500 | — | 503,750 |
| Faheem Hasnain | Option | 683,594 | 0.97 | — |
| Bryan Giraudo | Option | 66,094 | 1.21 | — |
| Faheem Hasnain | Option | 1,540,000 | 1.13 | — |
| Faheem Hasnain | Option | 209,636 | 0.84 | — |
| Faheem Hasnain | Option | 170,157 | 1.21 | — |
| Bryan Giraudo | Option | 283,204 | 0.97 | — |
| Faheem Hasnain | PSU | 437,500 | — | 1,356,250 |
| Robert Smith | Option | 750,000 | 0.97 | — |
| Bryan Giraudo | PSU | 181,250 | — | 561,875 |
| Faheem Hasnain | Option | 750,000 | 1.36 | — |
| Bryan Giraudo | Option | 86,850 | 0.84 | — |
| Robert Smith | Option | 572,000 | 1.13 | — |
| Robert Smith | Option | 487,500 | 0.97 | — |
The key objectives of our executive compensation program are: To attract, engage and retain an executive team who will provide leadership for our future success by providing competitive total pay opportunities. To establish a direct link between our business results, individual executive performance and total executive compensation. To align the interests of our named executive officers with those of our stockholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 111,286,550 | 7,545,502 | 137,461 | 93.65% | Passed |
| 2025 | 2025-06-25 | 125,358,485 | 3,769,651 | 472,930 | 97.08% | Passed |
| 2024 | 2024-06-06 | 115,985,182 | 40,356,919 | 5,831,133 | 74.19% | Passed |
| 2023 | 2023-06-08 | 38,901,355 | 19,975,931 | 87,316 | 66.07% | Passed |
| 2022 | 2022-06-09 | 46,093,471 | 345,876 | 31,930 | 99.26% | Passed |
| 2021 | 2021-06-09 | 50,886,375 | 298,541 | 2,688,857 | 99.42% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-04 | 93.65%a |
| 2025 | 2025-06-25 | 97.08%b |
| 2024 | 2024-06-06 | 74.19%c |
a. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.
b. Approved under the standard stated in the filing — “Abstentions are not an affirmative or negative vote on a proposal, so abstaining does not count as a vote cast and has no effect for purposes of determining whether our stockholders have ratified the appointment of Ernst & Young LLP, our independent registered public accounting firm, whether our stockholders have approved the compensation of the named executive officers, or whether our stockholders have approved the amendment and restatement our 2019 Incentive Award Plan.”.
c. Approved under the standard stated in the filing — “Abstentions are not an affirmative or negative vote on a proposal, so abstaining does not count as a vote cast and has no effect for purposes of determining whether our stockholders have ratified the appointment of Ernst & Young LLP, our independent registered public accounting firm, or whether our stockholders have approved the compensation of the named executive officers.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Thomas Daniel, M.DIndependent · Lead Independent Director · Compensation · Nominating/Governance | $76,875 | $0 | $122,694 | — | $0 | $199,569 |
| Russell CoxIndependent · Audit · Compensation (Chair) | 63,625 | 0 | 122,694 | — | 0 | 186,319 |
| Skye DrynanIndependent · Audit (Chair) | 58,750 | 0 | 122,694 | — | 0 | 181,444 |
| Sandra Milligan, M.D., J.DIndependent · Compensation · Nominating/Governance (Chair) | 56,625 | 0 | 122,694 | — | 0 | 179,319 |
| John Quisel, Ph.D., J.DIndependent · Audit | 49,375 | 0 | 122,694 | — | 0 | 172,069 |
| Steven Nathan, M.DIndependent · Nominating/Governance | 44,750 | 0 | 122,694 | — | 0 | 167,444 |
| Faheem HasnainEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $350,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $350,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Gossamer Bio names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Gossamer Bio.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | RAPT Therapeutics | 2024 | Brian Wong | $630,000 | $0 | $5,927,297 | $416,000 | $6,979,539 |
| 2 | Allakos | 2023 | Robert Alexander | 805,460 | 2,171,340 | 2,623,519 | 684,641 | 6,299,426 |
| 3 | Allogene Therapeutics | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 4 | AnaptysBio | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 5 | Mineralys Therapeutics | 2025 | Jon Congleton | 636,500 | 0 | 4,435,626 | 472,601 | 5,544,727 |
| 6 | Erasca | 2025 | Jonathan Lim | 670,400 | 0 | 3,135,250 | 482,688 | 4,298,838 |
| 7 | Trevi Therapeutics | 2025 | Jennifer Good | 622,382 | 0 | 2,968,260 | 0 | 3,944,892 |
| 8 | Poseida Therapeutics | 2023 | Mark Gergen | 611,667 | 1,442,285 | 1,413,936 | 336,420 | 3,818,018 |
| 9 | Annexon | 2025 | Douglas Love | 670,833 | 0 | 2,522,260 | 371,250 | 3,579,202 |
| 10 | aTyr Pharma | 2025 | Sanjay Shukla | 638,977 | 0 | 2,595,200 | 210,862 | 3,456,253 |
| 11 | Atea Pharmaceuticals | 2025 | Jean-Pierre Sommadossi | 703,490 | 1,315,800 | 962,368 | 422,094 | 3,403,752 |
| 12 | Fulcrum Therapeutics | 2025 | Alex Sapir | 650,000 | 0 | 2,052,132 | 411,200 | 3,251,490 |
| 13 | Kodiak Sciences | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 14 | Gossamer Bio | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 15 | Alector | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 16 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 17 | Zentalis Pharmaceuticals | 2025 | Julie Eastland | 700,000 | 99,772 | 56,975 | 441,000 | 1,300,731 |
| 18 | Ventyx Biosciences | 2024 | Raju Mohan | 621,920 | 0 | 303,800 | 342,045 | 1,283,015 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Gossamer Bio | 65% | not disclosed | No | Alpine Rewards |
| Alector | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allakos | not disclosed | Options 55 · RSU 45 | No | Compensia |
| Allogene Therapeutics | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| AnaptysBio | 110% | not disclosed | No | Alpine Rewards |
| Annexon | 100% of target% | not disclosed | not disclosed | Alpine Rewards |
| Atea Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| aTyr Pharma | 60% (Committee lowered payout from 75% achievement to 60% given EFZO-FIT study results)% | Option 100 | not disclosed | Radford |
| Erasca | 120% | Options 100 | not disclosed | Alpine Rewards, LLC |
| Fulcrum Therapeutics | not disclosed | Option 100 | not disclosed | Aon |
| Kodiak Sciences | 150% | Options 100 | not disclosed | Compensia, Inc. |
| Mersana Therapeutics | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Mineralys Therapeutics | not disclosed | Option 100 | not disclosed | not disclosed |
| Poseida Therapeutics | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| RAPT Therapeutics | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Trevi Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Ventyx Biosciences | not disclosed | not disclosed | not disclosed | AON/Radford |
| Zentalis Pharmaceuticals | 105% | not disclosed | not disclosed | Anderson Pay Advisors LLC / Pay Governance LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Faheem Hasnain | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Summary Compensation Table”. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568 |
| 2 | Section 01, Bryan Giraudo | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Summary Compensation Table”. As printed: 1,253,431. Filing ↗machine: r5 · c48 · span 385546–385555 |
| 3 | Section 01, Robert Smith | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Summary Compensation Table”. As printed: 1,180,744. Filing ↗machine: span 392612–392621 |
| 4 | Section 03, Faheem Hasnain OPTION | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r2 · c13 · span 377176–377185 |
| 5 | Section 03, Bryan Giraudo OPTION | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r5 · c13 · span 384546–384553 |
| 6 | Section 03, Robert Smith OPTION | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r8 · c13 · span 391387–391394 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-17 | 0001728117-26-000017 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Thomas Daniel, M.D | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 199,569. Filing ↗machine: t11 · r5 · c11 · span 195847–196153 |
| 9 | Section 08, Russell Cox | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 186,319. Filing ↗machine: t11 · r4 · c11 · span 193956–194262 |
| 10 | Section 08, Skye Drynan | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 181,444. Filing ↗machine: t11 · r3 · c11 · span 192148–192404 |
| 11 | Section 08, Sandra Milligan, M.D., J.D | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 179,319. Filing ↗machine: t11 · r6 · c10 · span 197449–197666 |
| 12 | Section 08, John Quisel, Ph.D., J.D | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 172,069. Filing ↗machine: t11 · r7 · c10 · span 199184–199426 |
| 13 | Section 08, Steven Nathan, M.D | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 167,444. Filing ↗machine: t11 · r2 · c11 · span 190463–190795 |
| 14 | Section 08, Faheem Hasnain | DEF 14A | 2026-04-24 | 0001728117-26-000027 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 02, Steven D. Nathan 2026-06-04 | Form 4 | 2026-06-05 | 0002015114-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Sandra Milligan 2026-06-04 | Form 4 | 2026-06-05 | 0001859810-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Russell Cox 2026-06-04 | Form 4 | 2026-06-05 | 0001512984-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Thomas O. Daniel 2026-06-04 | Form 4 | 2026-06-05 | 0001538894-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Skye Drynan 2026-06-04 | Form 4 | 2026-06-05 | 0002015102-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, John D. Quisel 2026-06-04 | Form 4 | 2026-06-05 | 0001728117-26-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Faheem Hasnain 2026-08-24 | Form 4 | 2026-08-26 | 0001352620-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Bryan Giraudo 2026-08-24 | Form 4 | 2026-08-26 | 0001740847-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Caryn Peterson 2026-08-24 | Form 4 | 2026-08-26 | 0001857256-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Waage Christian 2026-08-24 | Form 4 | 2026-08-26 | 0001553179-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Bryan Giraudo 2026-08-24 | Form 4 | 2026-08-26 | 0001740847-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Robert Smith 2026-08-24 | Form 4 | 2026-08-26 | 0002003059-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Faheem Hasnain 2026-08-24 | Form 4 | 2026-08-26 | 0001352620-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Steven D. Nathan 2026-09-23 | Form 4 | 2026-09-25 | 0001628280-26-063593 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Russell Cox 2026-09-23 | Form 4 | 2026-09-25 | 0001628280-26-063601 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, John D. Quisel 2026-09-23 | Form 4 | 2026-09-25 | 0001628280-26-063606 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Skye Drynan 2026-09-23 | Form 4 | 2026-09-25 | 0001628280-26-063610 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Gregory Austin Ciongoli 2026-09-23 | Form 4 | 2026-09-25 | 0001628280-26-063616 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Thomas O. Daniel 2026-09-23 | Form 4 | 2026-09-25 | 0001628280-26-063619 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Sandra Milligan 2026-09-23 | Form 4 | 2026-09-25 | 0001628280-26-063624 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 06, 2026 vote | Form 8-K | 2026-06-05 | 0001728117-26-000042 | Item 5.07 · say-on-pay result. As reported: 93.65% (votes for as printed: 111,286,550). Filing ↗ |
| 36 | Section 06, 2025 vote | Form 8-K | 2025-06-25 | 0001728117-25-000043 | Item 5.07 · say-on-pay result. As reported: 97.08% (votes for as printed: 125,358,485). Filing ↗ |
| 37 | Section 06, 2024 vote | Form 8-K | 2024-06-10 | 0001728117-24-000069 | Item 5.07 · say-on-pay result. As reported: 74.19% (votes for as printed: 115,985,182). Filing ↗ |
| 38 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 39 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 40 | Section 09b board cost (computed) | Computed | — | — | Cash 350,000 + equity 0 + all other 0 = 350,000, summed across the director compensation table rows.machine: formula: Σ = 350,000 |
| 41 | RAPT Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-14 | 0000950170-25-053517 | CEO total compensation as printed in RAPT Therapeutics's own proxy. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861 |
| 42 | Allakos, Section 10b CEO total | DEF 14A | 2024-04-23 | 0000950170-24-047043 | CEO total compensation as printed in Allakos's own proxy. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107 |
| 43 | Allogene Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028948 | CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023 |
| 44 | AnaptysBio, Section 10b CEO total | DEF 14A | 2026-06-29 | 0001193125-26-288408 | CEO total compensation as printed in AnaptysBio's own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415 |
| 45 | Mineralys Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001933414-26-000069 | CEO total compensation as printed in Mineralys Therapeutics's own proxy. As printed: 5,544,727. Filing ↗machine: r2 · c48 · span 235758–235767 |
| 46 | Erasca, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187361 | CEO total compensation as printed in Erasca's own proxy. As printed: 4,298,838. Filing ↗machine: r2 · c31 · span 221524–221533 |
| 47 | Trevi Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001193125-26-166695 | CEO total compensation as printed in Trevi Therapeutics's own proxy. As printed: 3,944,892. Filing ↗machine: r2 · c21 · span 594331–594340 |
| 48 | Poseida Therapeutics, Section 10b CEO total | DEF 14A | 2024-04-25 | 0000950170-24-048291 | CEO total compensation as printed in Poseida Therapeutics's own proxy. As printed: 3,818,018. Filing ↗machine: span 428155–428164 |
| 49 | Annexon, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001140361-26-017085 | CEO total compensation as printed in Annexon's own proxy. As printed: 3,579,202. Filing ↗machine: r2 · c24 · span 356205–356214 |
| 50 | aTyr Pharma, Section 10b CEO total | DEF 14A | 2026-03-26 | 0001339970-26-000021 | CEO total compensation as printed in aTyr Pharma's own proxy. As printed: 3,456,253. Filing ↗machine: r2 · c21 · span 533754–533763 |
| 51 | Atea Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182293 | CEO total compensation as printed in Atea Pharmaceuticals's own proxy. As printed: 3,403,752. Filing ↗machine: r3 · c22 · span 1526943–1526952 |
| 52 | Fulcrum Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197196 | CEO total compensation as printed in Fulcrum Therapeutics's own proxy. As printed: 3,251,490. Filing ↗machine: r2 · c25 · span 336588–336597 |
| 53 | Kodiak Sciences, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170429 | CEO total compensation as printed in Kodiak Sciences's own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068 |
| 54 | Gossamer Bio (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001728117-26-000027 | CEO total compensation as printed in Gossamer Bio's own proxy. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568 |
| 55 | Alector, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 56 | Mersana Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001104659-25-040448 | CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. Filing ↗machine: r1 · c41 · span 608188–608197 |
| 57 | Zentalis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001725160-26-000027 | CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. Filing ↗machine: r2 · c48 · span 319348–319357 |
| 58 | Ventyx Biosciences, Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-057384 | CEO total compensation as printed in Ventyx Biosciences's own proxy. As printed: 1,283,015. Filing ↗machine: r2 · c25 · span 569480–569489 |
| 59 | Section 10a, Zentalis Pharmaceuticals reciprocity | DEF 14A | — | 0001725160-23-000078 | Zentalis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 60 | Section 10a, Allogene Therapeutics reciprocity | DEF 14A | — | 0001628280-26-028948 | Allogene Therapeutics's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 61 | Section 10a, Atea Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-182293 | Atea Pharmaceuticals names Gossamer Bio in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 62 | Section 10a, Alector reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 63 | Section 10a, aTyr Pharma reciprocity | DEF 14A | — | 0001339970-26-000021 | aTyr Pharma names Gossamer Bio in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 64 | Section 10a, Trevi Therapeutics reciprocity | DEF 14A | — | 0001193125-26-166695 | Trevi Therapeutics's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 65 | Section 10a, Kodiak Sciences reciprocity | DEF 14A | — | 0001193125-26-170429 | Kodiak Sciences's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 66 | Section 10a, Allakos reciprocity | DEF 14A | — | 0000950170-24-047043 | Allakos's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 67 | Section 10a, Mersana Therapeutics reciprocity | DEF 14A | — | 0001104659-25-040448 | Mersana Therapeutics's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
| 68 | Section 10a, AnaptysBio reciprocity | DEF 14A | — | 0001193125-26-288408 | AnaptysBio's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.